Poster Presentation on ALE.F02 as Potential Treatment for Kidney Fibrosis
Basel, Switzerland – 26 Oct 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today a poster presentation on the first day of the American Society of Nephrology (ASN) Kidney Week being held November 2-5, 2023, in Philadelphia, PA, USA.
- Title: Claudin-1 is a therapeutic target for crescentic glomerulonephritis (Abstract TH-PO531)
- Presenter: Geoffrey Teixeira, SVP Head of Fibrosis, Alentis Therapeutics
- Session: Glomerular Diseases: From Inflammation to Fibrosis (1401)
- Date and time: Thursday, November 2, from 10:00 am to 12:00 pm ET
Dr. Luigi Manenti, Chief Medical Officer of Alentis said, “Crescentic glomerulonephritis, or CGN, is a spectrum of diseases characterized by kidney fibrosis for which new effective therapies are desperately needed. During the ASN Kidney Week we will present preclinical proof-of-concept data showing ALE.F02 is a potential treatment for CGN in ANCA-associated vasculitis, Lupus nephritis and crescentic IgA nephropathy.“
Prof. Pierre-Louis Tharaux, Paris Cardiovascular Research Center, PARCC, said, “Targeting glomerular parietal epithelial cell activation may offer a novel and original mode of action to treat severe extracapillary glomerulonephritis such as CGN.“
ALE.F02 is a first-in-class monoclonal antibody developed for liver, lung and kidney fibrosis. The investigational antibody is designed to reverse organ fibrosis by specifically targeting a unique CLDN1 epitope exposed in fibrotic tissue. In Phase 1 single- and multiple-ascending dose studies in healthy volunteers ALE.F02 was observed to be well tolerated, with no serious safety concerns. ALE.F02 is currently tested in clinical trials for advanced liver fibrosis (NCT05939947) and ANCA-associated vasculitis (NCT06047171).
About Alentis Therapeutics
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is the leading company pioneering a novel approach to modify and reverse the course of disease by targeting CLDN1, a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease.
Alentis was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert, MD at the University of Strasbourg and the French National Institute of Health and Medical Research (Inserm). Alentis is headquartered in pharma-biotech hub Basel, Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US. Visit https://alentis.ch
For more information please contact: